Glenmark unveils FDC drug for Asthma in India

Mumbai: Glenmark Pharmaceuticals Limited, an innovation-driven global pharmaceutical company has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India.

The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.

While speaking on the development, Alok Malik, Group Vice President & Head, India Formulations – Glenmark Pharmaceuticals Ltd. said, "Respiratory is a key focus area for Glenmark and the company leads from the front in providing access to the latest treatment options to patients. We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma."

Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid which is approved by the DCGI (Drug Controller General of India).

Asthma is a major non-communicable disease (NCD), affecting both children and adults caused due to inflammation and narrowing of the small airways in the lungs. Asthma affects more than 34 million people in India, causing thousands of deaths every year.

According to the Global Burden of Disease report by the Institute for Health Metrics and Evaluation (IHME), asthma accounted for 27.9% of disability-adjusted life years (DALYs) in Indians causing 3 times higher mortality and 2 times higher DALYs compared to the global proportion of asthma. Out of the total asthmatic patients undergoing conventional treatment in India, up to 49% have uncontrolled asthma.

Indamet will help in the management of uncontrolled asthma by improving lung function, better symptom control and reducing exacerbations.

Read also: Glenmark Gets CDSCO panel nod to market asthma, COPD drug